Interpretation of Guidelines for the management of non-ST elevation acute coronary syndromes (2024)
-
摘要: 中华医学会心血管病学分会发布了《非ST段抬高型急性冠脉综合征诊断和治疗指南(2024)》，新版指南在2016版指南基础上，参考最新循证医学证据和国际指南，结合我国国情及临床实践经验，对非ST段抬高型急性冠脉综合征(NSTE-ACS)的管理作出了最新推荐。本文就指南的重要推荐更新进行逐一解读，以期为NSTE-ACS的临床诊疗实践提供帮助。Abstract: The Cardiovascular Disease Branch of the Chinese Medical Association has released the Guidelines for the management of non-ST elevation acute coronary syndromes. Based on the 2016 guidelines, the new guidelines refer to the latest evidence-based medicine and international guidelines, and combine China's national conditions and clinical practice experience to make the latest recommendations for the management of non-ST elevation acute coronary syndrome (NSTE-ACS). This article interprets the important recommendations and updates of the guidelines one by one, in order to provide assistance for the clinical diagnosis and treatment of NSTE-ACS.
-
Key words:
- acute coronary syndrome /
- diagnosis /
- treatment /
- guideline
-
-
[1] 中华医学会心血管病学分会与中华心血管病杂志编辑委员会. 非ST段抬高型急性冠脉综合征诊断和治疗指南(2024)[J]. 中华心血管病杂志, 2024, 52(6): 615-646. doi: 10.3760/cma.j.cn112148-20240107-00014
[2] Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14): 1289-1367. doi: 10.1093/eurheartj/ehaa575
[3] Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38): 3720-3826. doi: 10.1093/eurheartj/ehad191
[4] Han YL, Chen JY, Qiu MH, et al. Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: The OPT-CAD risk score[J]. Cardiovasc Ther, 2018, 36(5): e12441. doi: 10.1111/1755-5922.12441
[5] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057. doi: 10.1056/NEJMoa0904327
[6] Wu H, Xu L, Zhao X, et al. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation(OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial[J]. Circulation, 2023, 147(3): 212-222. doi: 10.1161/CIRCULATIONAHA.122.062762
[7] Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients[J]. Eur Heart J, 2017, 38(14): 1034-1043.
[8] Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials[J]. BMJ, 2021, 373: n1332.
[9] Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial[J]. JAMA Cardiol, 2022, 7(4): 407-417. doi: 10.1001/jamacardio.2021.5244
[10] Han YL, Claessen BE, Chen SL, et al. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy[J]. Circ Cardiovasc Interv, 2022, 15(4): e009495.
[11] Valgimigli M, Frigoli E, Heg D, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk[J]. N Engl J Med, 2021, 385(18): 1643-1655. doi: 10.1056/NEJMoa2108749
[12] Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention(HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial[J]. Lancet, 2021, 397(10293): 2487-2496. doi: 10.1016/S0140-6736(21)01063-1
[13] Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study[J]. Eur Heart J, 2017, 38(41): 3070-3078. doi: 10.1093/eurheartj/ehx175
[14] Han YL, Guo HC, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial[J]. JAMA, 2015, 313(13): 1336-1346. doi: 10.1001/jama.2015.2323
[15] Zhang JJ, Gao XF, Kan J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: The ULTIMATE Trial[J]. J Am Coll Cardiol, 2018, 72(24): 3126-3137. doi: 10.1016/j.jacc.2018.09.013
[16] Prati F, Vito D, Biondi-Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention(CLI-OPCI)study[J]. EuroIntervention, 2012, 8(7): 823-829. doi: 10.4244/EIJV8I7A125
[17] Koo BK, Hu X, Kang J, et al. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI[J]. N Engl J Med, 2022, 387(9): 779-789. doi: 10.1056/NEJMoa2201546
[18] Layland J, Oldroyd KG, Curzen N, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial[J]. Eur Heart J, 2015, 36(2): 100-111. doi: 10.1093/eurheartj/ehu338
[19] Yang JJ, Shan DK, Wang X, et al. On-Site Computed Tomography-Derived Fractional Flow Reserve to Guide Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial[J]. Circulation, 2023, 147(18): 1369-1381. doi: 10.1161/CIRCULATIONAHA.123.063996
[20] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(3): e18-e114.
[21] Sardella G, Lucisano L, Garbo R, et al. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial[J]. J Am Coll Cardiol, 2016, 67(3): 264-272. doi: 10.1016/j.jacc.2015.10.082
[22] Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34): 3227-3337. doi: 10.1093/eurheartj/ehab484
[23] Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease[J]. N Engl J Med, 2020, 383(19): 1838-1847. doi: 10.1056/NEJMoa2021372
[24] Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. doi: 10.1056/NEJMoa1912388
-
计量
- 文章访问数: 642
- 施引文献: 0
下载: